MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Guardant Health Inc

Closed

SectorHealthcare

48.14 1.65

Overview

Share price change

24h

Current

Min

47.65

Max

48.19

Key metrics

By Trading Economics

Income

-3.3M

-111M

Sales

10M

202M

EPS

-0.62

Profit margin

-55.004

Employees

1,999

EBITDA

-2.7M

-99M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+17.41% upside

Dividends

By Dow Jones

Next Earnings

30 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-795M

5.3B

Previous open

46.49

Previous close

48.14

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Guardant Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 kwi 2025, 23:55 UTC

Market Talk

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

27 kwi 2025, 23:47 UTC

Market Talk

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

27 kwi 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

27 kwi 2025, 23:12 UTC

Earnings

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

27 kwi 2025, 23:12 UTC

Earnings

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

27 kwi 2025, 20:41 UTC

Earnings

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

27 kwi 2025, 20:41 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

27 kwi 2025, 20:41 UTC

Earnings

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

27 kwi 2025, 18:41 UTC

Top News

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

27 kwi 2025, 11:00 UTC

Top News

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

27 kwi 2025, 05:41 UTC

Earnings

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

27 kwi 2025, 05:41 UTC

Earnings

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

27 kwi 2025, 05:41 UTC

Earnings

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

27 kwi 2025, 05:41 UTC

Earnings

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

27 kwi 2025, 05:41 UTC

Earnings

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

27 kwi 2025, 05:41 UTC

Earnings

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

27 kwi 2025, 05:34 UTC

Earnings

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

27 kwi 2025, 05:34 UTC

Earnings

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

27 kwi 2025, 05:34 UTC

Earnings

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

27 kwi 2025, 05:29 UTC

Earnings

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

27 kwi 2025, 05:29 UTC

Earnings

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

27 kwi 2025, 05:29 UTC

Earnings

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

27 kwi 2025, 05:29 UTC

Earnings

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

27 kwi 2025, 05:21 UTC

Earnings

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

27 kwi 2025, 05:21 UTC

Earnings

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

27 kwi 2025, 05:21 UTC

Earnings

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

27 kwi 2025, 05:21 UTC

Earnings

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

27 kwi 2025, 03:00 UTC

Top News

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

27 kwi 2025, 00:30 UTC

Top News

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

27 kwi 2025, 00:30 UTC

Top News

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

17.41% upside

12 Months Forecast

Average 56.71 USD  17.41%

High 65 USD

Low 50 USD

Based on 20 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

20

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

45.16 / N/ASupport & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.